Every 10-Q that Avanos Medical, Inc. (AVNS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AVNS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVNS filings page.
Avanos Medical reported first-quarter 2026 results and outlined a pending cash merger that will take the company private. Net sales rose to $182.2 million from $167.5 million, driven mainly by Specialty Nutrition Systems, while net income declined to $5.1 million from $6.6 million, or $0.11 per diluted share.
Specialty Nutrition Systems revenue grew to $124.0 million, including contributions from the 2025 Nexus acquisition, while Pain Management and Recovery was roughly flat at $56.3 million. Operating income was $8.9 million, and adjusted operating income was $16.2 million, reflecting restructuring and acquisition-related costs.
Cash and equivalents were $65.6 million and term loan debt was $98.4 million, with operating activities using $12.3 million of cash in the quarter. A restructuring plan tied to the 2023 Respiratory Health divestiture has generated $43.1 million of cumulative expenses and is expected to run through 2026.
After quarter-end, Avanos agreed to be acquired by affiliates of American Industrial Partners for $25.00 per share in cash, with all shares and equity awards to be cashed out at closing. The transaction requires shareholder approval and regulatory clearances and, if completed, will result in Avanos being delisted from the New York Stock Exchange.
Avanos Medical (AVNS) reported Q3 2025 results showing modest top-line growth but weaker profitability. Net sales were $177.8 million versus $170.4 million a year ago, driven by Specialty Nutrition Systems (SNS) at $114.0 million and Pain Management & Recovery (PM&R) at $59.0 million. Gross profit fell to $86.0 million from $92.9 million as cost of products sold increased. Operating income was $0.1 million, and the company posted a net loss of $1.4 million (diluted EPS $(0.03)).
Year to date, net sales reached $520.3 million versus $508.2 million, with an operating loss of $64.1 million reflecting a $77.0 million goodwill impairment in PM&R recorded earlier in 2025. Net loss was $71.6 million (diluted EPS $(1.55)). Cash and cash equivalents were $70.5 million, down from $107.7 million at year-end, after funding investments and debt repayments; the revolver was reduced to $0 and the term loan stood at $103.1 million.
Strategic moves included acquiring Nexus Medical for $27.0 million in cash (up to $20.0 million contingent). The deal added $0.9 million of net sales since closing and brought $20.5 million of identifiable intangibles and $14.0 million of goodwill. Restructuring continued, with $10.3 million in Q3 costs; management expects up to $10.0 million additional expenses and annualized savings of $15.0–$20.0 million as initiatives extend through 2026.